Vir Biotechnology rises after naming Theravance's Sawaf as CFO
VIR•Vir Biotechnology shares rose more than 3% to $11.53 in afternoon trading after the company named Aziz Sawaf chief financial officer, effective Oct. 5.
1. CFO appointment
Sawaf joins Vir from Theravance Biopharma, where he was CFO from 2023. He succeeds Jason O'Byrne, who left Vir on Aug. 3 to pursue another opportunity.
2. Analyst outlook
All 10 analysts covering Vir are bullish, with a median price target of $20, according to data compiled by LSEG. Including the session's move, the stock was up 91% year to date.
